ReviewBest practice & research. Clinical haematology2010
Autoimmune complications in chronic lymphocytic leukaemia (CLL).
Review in Best practice & research. Clinical haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.Acta clinica Croatica · 2018Guideline
- Chronic lymphocytic leukemia and autoimmunity: a systematic review.Haematologica · 2011Pooled it
- Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).Acta haematologica · 2019Trial
- Postoperative Complications Following Total Knee Arthroplasty in Patients with Chronic Lymphocytic Leukemia.Journal of clinical medicine · 2026Article
- Review
- Article
- BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.Biomolecules · 2026Review
- Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Post-infantile Giant Cell Hepatitis: A Literature Review and Meta-analysis.Journal of clinical and translational pathology · 2022Article
- Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives.Molecules (Basel, Switzerland) · 2022Article
- Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.British journal of haematology · 2022Article
- Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.Current oncology (Toronto, Ont.) · 2022Article
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high-dose methylprednisolone, revisited.Cancer medicine · 2021Article
- Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar-Cases Series and a Review of the Literature.International journal of molecular sciences · 2021Review
- Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?The American journal of case reports · 2021Article
- Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review.Journal of blood medicine · 2021Article
- Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.Scientific reports · 2020Article
- High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.Journal of cell science · 2020Article
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.Blood · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Patients with B-chronic lymphocytic leukaemia /small lymphocytic lymphoma (CLL) have a 5-10% risk of developing autoimmune complications, which primarily cause cytopaenia. These autoimmune cytopaenias can occur at any stage of CLL and do not have independent prognostic significance. The most common autoimmune complication is autoimmune haemolytic anaemia with a lower frequency of immune thrombocytopaenia and pure red blood cell aplasia and only rarely, autoimmune granulocytopaenia (AIG). Autoimmune cytopaenia should always be considered in the differential diagnosis of cytopaenia in patients with CLL. Patients with CLL can also have more than one form of autoimmune cytopaenia, which can occur together with bone-marrow failure. Treatment is usually effective but rarely curative for autoimmune cytopaenia complicating CLL. Optimal therapy will depend on a timely and accurate diagnosis of autoimmune cytopaenia and should be individualised according to the severity of the cytopaenia and the presence or absence of concomitant progressive CLL requiring therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.